QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
Log in

Intra-Cellular Therapies Stock Forecast, Price & News

-0.36 (-1.05 %)
(As of 01/15/2021 08:00 PM ET)
Today's Range
Now: $33.78
50-Day Range
MA: $28.97
52-Week Range
Now: $33.78
Volume15,548 shs
Average Volume667,880 shs
Market Capitalization$2.71 billion
P/E RatioN/A
Dividend YieldN/A
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Intra-Cellular Therapies logo


Overall MarketRank

1.87 out of 5 stars

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ITCI



Sales & Book Value

Annual Sales$60,000.00
Price / Sales45,128.95
Book Value$3.52 per share


Net Income$-147,720,000.00
Net Margins-1,985.32%


Market Cap$2.71 billion
Next Earnings Date3/1/2021 (Estimated)
-0.36 (-1.05 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

How has Intra-Cellular Therapies' stock been impacted by Coronavirus?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ITCI stock has increased by 90.1% and is now trading at $33.78.
View which stocks have been most impacted by COVID-19

Is Intra-Cellular Therapies a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Intra-Cellular Therapies?

Wall Street analysts have given Intra-Cellular Therapies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intra-Cellular Therapies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Intra-Cellular Therapies

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) posted its quarterly earnings data on Saturday, November, 14th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.00) by $0.21. The biopharmaceutical company had revenue of $7.37 million for the quarter, compared to the consensus estimate of $6.52 million. Intra-Cellular Therapies had a negative net margin of 1,985.32% and a negative return on equity of 48.27%.
View Intra-Cellular Therapies' earnings history

What price target have analysts set for ITCI?

9 analysts have issued 12-month target prices for Intra-Cellular Therapies' stock. Their forecasts range from $26.00 to $70.00. On average, they expect Intra-Cellular Therapies' share price to reach $44.75 in the next year. This suggests a possible upside of 32.5% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies
or view Wall Street analyst' top-rated stocks.

Who are some of Intra-Cellular Therapies' key competitors?

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:
  • Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 68, Pay $1.52M)
  • Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 65, Pay $693.55k)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 48, Pay $837.47k)
  • Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 58, Pay $914.35k)
  • Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 70)
  • Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 50)
  • Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 59)
  • Dr. Suresh K. Durgam M.D., Sr. VP & Chief Medical Officer
  • Dr. Michael Olchaskey, Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include First Midwest Bank Trust Division (0.17%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies

Which major investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies
or view top insider-selling stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $33.78.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $2.71 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 330 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.